EA200000220A1 - Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы - Google Patents

Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы

Info

Publication number
EA200000220A1
EA200000220A1 EA200000220A EA200000220A EA200000220A1 EA 200000220 A1 EA200000220 A1 EA 200000220A1 EA 200000220 A EA200000220 A EA 200000220A EA 200000220 A EA200000220 A EA 200000220A EA 200000220 A1 EA200000220 A1 EA 200000220A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemical sterilization
treatment
combination
prostate gland
inhibitor
Prior art date
Application number
EA200000220A
Other languages
English (en)
Other versions
EA002525B1 (ru
Inventor
Крэйг А. Дайонн
Джон Исаакс
Джеффри Л. Вот
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22000842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000220(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of EA200000220A1 publication Critical patent/EA200000220A1/ru
Publication of EA002525B1 publication Critical patent/EA002525B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Раскрывается способ лечения рака предстательной железы при совместном введении ингибитора тирозинкиназы, такого как индолокарбазол, и средства для химической стерилизации. Раскрывается также композиция, содержащая ингибитор тирозинкиназы и средство для химической стерилизации.Отчет о международном поиске был опубликован1999.04.15.
EA200000220A 1997-08-15 1998-08-13 Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы EA002525B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5589197P 1997-08-15 1997-08-15
PCT/US1998/016849 WO1999008668A2 (en) 1997-08-15 1998-08-13 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer

Publications (2)

Publication Number Publication Date
EA200000220A1 true EA200000220A1 (ru) 2000-10-30
EA002525B1 EA002525B1 (ru) 2002-06-27

Family

ID=22000842

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000220A EA002525B1 (ru) 1997-08-15 1998-08-13 Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы

Country Status (23)

Country Link
US (1) US5985877A (ru)
EP (1) EP1011648B2 (ru)
JP (1) JP2001515032A (ru)
KR (1) KR100612161B1 (ru)
CN (1) CN1147317C (ru)
AT (1) ATE208210T1 (ru)
AU (1) AU737092B2 (ru)
BR (1) BR9812122A (ru)
CA (1) CA2299471C (ru)
CZ (1) CZ297198B6 (ru)
DE (1) DE69802422T3 (ru)
DK (1) DK1011648T4 (ru)
EA (1) EA002525B1 (ru)
ES (1) ES2163293T5 (ru)
HK (1) HK1028565A1 (ru)
HU (1) HUP0003194A3 (ru)
NO (1) NO325526B1 (ru)
NZ (2) NZ502646A (ru)
PL (1) PL193375B1 (ru)
PT (1) PT1011648E (ru)
TR (1) TR200000415T2 (ru)
UA (1) UA61970C2 (ru)
WO (1) WO1999008668A2 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
SK14632003A3 (sk) * 2001-05-08 2004-03-02 Merck Patent Gmbh Kombinovaná terapia pri použití anti-EGFR protilátok a antihormonálnych činidiel
SE0101697D0 (sv) * 2001-05-14 2001-05-14 Astrazeneca Ab Pharmaceutical combination
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
EP2518142B1 (en) * 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
ES2366380T3 (es) 2005-06-14 2011-10-19 Protox Therapeutics Incorporated Método para el tratamiento o prevención de hiperplasia prostática benigna utilizando proteínas formadoras de poros modificadas.
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
MY162024A (en) 2006-08-28 2017-05-31 La Jolla Inst Allergy & Immunology Antagonistic human light-specific human monoclonal antibodies
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
US20090130195A1 (en) * 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
RU2699289C2 (ru) 2013-08-26 2019-09-04 Байонтек Рисерч Энд Дивелопмент, Инк. НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015271685B2 (en) 2014-06-04 2021-02-18 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
AU2016271040A1 (en) * 2015-05-29 2017-11-23 Cornell University Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018217528A1 (en) 2017-05-25 2018-11-29 Memorial Sloan Kettering Cancer Center Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
RU2667906C1 (ru) * 2017-09-11 2018-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
AU2019306165A1 (en) 2018-07-20 2021-02-25 Pierre Fabre Medicament Receptor for vista

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) † 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
WO1988007045A1 (en) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5461146A (en) † 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
ES2118414T3 (es) * 1993-05-28 1998-09-16 Cephalon Inc Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
SE506019C2 (sv) * 1994-05-17 1997-11-03 Forskarpatent I Linkoeping Ab Ljuskälla av konjugerade polymerer med spänningsstyrd färg samt metod för tillverkning av ljuskällan
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) † 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5659407A (en) * 1995-06-06 1997-08-19 Apple Computer, Inc. Method and system for rendering achromatic image data for image output devices
EP0912562A1 (en) † 1996-07-19 1999-05-06 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
EA002525B1 (ru) 2002-06-27
NZ517497A (en) 2004-11-26
ATE208210T1 (de) 2001-11-15
CZ2000469A3 (cs) 2001-08-15
TR200000415T2 (tr) 2000-08-21
CN1268061A (zh) 2000-09-27
EP1011648B1 (en) 2001-11-07
DE69802422D1 (de) 2001-12-13
NO20000732L (no) 2000-03-28
NO20000732D0 (no) 2000-02-14
DE69802422T3 (de) 2005-12-29
HUP0003194A3 (en) 2003-03-28
EP1011648A2 (en) 2000-06-28
PT1011648E (pt) 2002-03-28
UA61970C2 (en) 2003-12-15
CN1147317C (zh) 2004-04-28
CA2299471C (en) 2007-12-18
NO325526B1 (no) 2008-06-02
AU737092B2 (en) 2001-08-09
JP2001515032A (ja) 2001-09-18
WO1999008668A2 (en) 1999-02-25
DK1011648T3 (da) 2001-12-27
EP1011648B2 (en) 2005-07-20
ES2163293T5 (es) 2006-01-16
PL193375B1 (pl) 2007-02-28
DK1011648T4 (da) 2005-10-24
CA2299471A1 (en) 1999-02-25
KR20010022878A (ko) 2001-03-26
ES2163293T3 (es) 2002-01-16
HUP0003194A2 (hu) 2001-07-30
PL338885A1 (en) 2000-11-20
WO1999008668A3 (en) 1999-04-15
US5985877A (en) 1999-11-16
NZ502646A (en) 2002-04-26
AU9019298A (en) 1999-03-08
CZ297198B6 (cs) 2006-09-13
BR9812122A (pt) 2000-07-18
HK1028565A1 (en) 2001-02-23
DE69802422T2 (de) 2002-07-11
KR100612161B1 (ko) 2006-08-14

Similar Documents

Publication Publication Date Title
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
EA199800667A1 (ru) Новые фенантридины
BR9608651A (pt) Método para o tratamento de hiperplasia prostática benigna com terapia térmica
ATE399007T1 (de) Raf kinase hemmer
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MY121548A (en) Compounds and methods for the treatment of cancer
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
EA199900324A1 (ru) Комбинированная терапия для лечения психозов
EA199900620A1 (ru) Фталазиноны
BR9805544A (pt) Uso de um composto.
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
EA199800011A1 (ru) Способ лечения или предупреждения остеопороза
EP0646007A1 (en) NEW DELTA-17 AND DELTA-20 UNSATURATED AND SATURATED 17 - g (b) -SUBSTITUTED-4-AZA-5-g (a) -ANDROSTAN-3-ON COMPOUNDS AS INHIBITORS OF 5-ALPHA REDUCTASE.
EA200000519A1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
IT1270993B (it) Derivati chinzolilamminici attivi come alfa-antagonisti
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
NO984631D0 (no) <alfa>1-Adrenerge reseptor-antagonister
EA199900534A1 (ru) Имидазопиридазины
EA200000522A1 (ru) 5-htагонисты
EA199800535A1 (ru) Способ лечения боли
EA199800533A1 (ru) Композиция для лечения боли
EA199800058A1 (ru) Способ лечения доброкачественной гиперплазии предстательной железы, лекарственная форма для лечения доброкачественной гиперплазии, содержащая агонист мелатонина
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU